OXBRYTA

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Lithuania, Poland.

Active ingredients

The drug OXBRYTA contains one active pharmaceutical ingredient (API):

1	Voxelotor UNII 3ZO554A4Q8 - VOXELOTOR
	Voxelotor is a haemoglobin S (HbS) polymerisation inhibitor that binds to HbS with a 1:1 stoichiometry and exhibits preferential partitioning to red blood cells (RBCs). By increasing the affinity of Hb for oxygen, voxelotor demonstrates dose-dependent inhibition of HbS polymerisation. Voxelotor inhibits RBC sickling and improves RBC deformability.
	Read more about Voxelotor

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
OXBRYTA Film-coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)
OXBRYTA Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B06AX03		B Blood and blood forming organs → B06 Other hematological agents → B06A Other hematological agents → B06AX Other hematological agents
Discover more medicines within B06AX03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1875999
FR	Base de données publique des médicaments	62137714
IT	Agenzia del Farmaco	049971017
LT	Valstybinė vaistų kontrolės tarnyba	1094267
PL	Rejestru Produktów Leczniczych	100465932
US	FDA, National Drug Code	72786-101